University of Oklahoma Health Sciences Center

Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults

Author/s:

Kumar, A, Nalawade, V, Riviere, P, Sarkar, RR, Parsons, JK, Murphy, JD, Rose, BS

Read more about Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults
Log in or register to post comments

5α-reductase inhibitors (5-ARIs) are used to treat benign prostatic enlargement, a common condition causing urinary outflow obstruction. They also reduce prostate-specific antigen (PSA) by approximately 50%. Our group has recently published that among US military veterans, 5-ARIs are associated with delays in prostate cancer (PC) diagnoses, higher grade and stage at presentation, and worse PC-specific mortality (PCSM), presumably because of misinterpreted PSA values. We hypothesized that these results are generalizable to the broader US population.

Keywords

prostate cancer 5-alpha-reductase inhibitors 5α-Reductase Inhibitors 5-ARIs prostate-specific antigen PSA